Manus is constructing a new building at its Augusta BioFacility to bring new cGMP capabilities to the site, combining biomanufacturing and flow chemistry under one roof to onshore U.S. production of artemisinin.

Manus is the world’s leading bioalternatives scale-up platform. We work with companies across industries and value chains to accelerate the transition to bioalternatives – better performing and more sustainable versions of complex molecules traditionally sourced from plants, animals, or fossil fuels. Our platform is proven to work across scales, bridging the Valley of Death between lab and manufacturing more efficiently and more reliably to deliver the benefits of biomanufacturing, today.